Holen Sie sich die Stockscreener-App
498.43
4.56%
-23.82
Vorhandelsmarkt:
499.09
0.66
+0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$522.25
Offen:
$523.04
24-Stunden-Volumen:
2.22M
Relative Volume:
1.54
Marktkapitalisierung:
$126.50B
Einnahmen:
$12.34B
Nettoeinkommen (Verlust:
$4.34B
KGV:
29.55
EPS:
16.8685
Netto-Cashflow:
$3.71B
1W Leistung:
+0.08%
1M Leistung:
+12.52%
6M Leistung:
+6.12%
1J Leistung:
+6.88%
1-Tages-Spanne:
$498.14
$525.81
1-Wochen-Bereich:
$498.14
$533.67
52-Wochen-Spanne:
$362.50
$533.67
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex’s $10 Billion Crinetics Acquisition Lands Amid Record Stock High: Time to Buy? - NAI500
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled - TradingKey
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc.CRNX - Business Wire
Vertex Pharmaceutical agrees to buy Crinetics in US$10 billion deal - BNN Bloomberg
Vertex’s Crinetics Deal Balances Growth with Integration Risk - MarketBeat
PR News | Joele Frank Works Crinetics' $8.8B DealWed., Jul. 8, 2026 - O'Dwyer's PR
Vertex’s Crinetics Deal Balances Growth with Integration Risk - Investing.com
Stifel cuts Crinetics stock rating to hold on Vertex acquisition - Investing.com
Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal - Yahoo Finance
American Vertex Pharmaceuticals acquires Crinetics for $10 billion - AKM.RU
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside - Trefis
Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580 - Moomoo
Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now? - Yahoo Finance
H.C. Wainwright reiterates Vertex stock Buy rating at $641 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Morgan Stanley Analyzes Vertex Pharmaceuticals' (VRTX.US) $10 Billion Acquisition of Crinetics: Completing Its Endocrinology Pipeline and Unlocking Growth Potential with Two Core Drugs - Moomoo
Vertex to acquire Crinetics in deal worth around $10.0bn - PMLiVE
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil - BioSpace
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. - AOL.com
Vertex Pharmaceuticals Inc Stock Price Live, Charts & News - The Economic Times
Key facts: Vertex to Buy Crinetics for $10B at $85; RBC Raises Target; Q2 Results Aug 3 - TradingView
The $10B Integration Problem Vertex Hasn’t Solved Yet - The Clinical Trial Vanguard
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal? - Stocktwits
Narrow-Moat Vertex's Strong CF Cash Flows Support Expansion Into Endocrinology Via Crinetics - Morningstar
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. - The Globe and Mail
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout - Yahoo Finance
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals in $10 Billion All-Cash Deal - Global Legal Chronicle
Investigation launched into Crinetics Pharma bo... - Pluang
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Vertex Pharma’s Growth Strategy Leads to Its Biggest-Ever M&A Deal - MedCity News
Healthcare Deals This Week: AstraZeneca, Novartis, Vertex - Law360
Vertex Pharmaceuticals EVP sells $787,485 in company stock - Investing.com
Vertex Pharmaceuticals EVP sells $787,485 in company stock By Investing.com - Investing.com Nigeria
Form 4 Vertex Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology - Yahoo Finance
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd - Business Wire
Why Crinetics (NASDAQ:CRNX) Nearly Doubled Today After Vertex’s US$10 Billion Takeover - Stocks Down Under
The Changing Reality of Pharmaceutical Commercialization | PharmExec - Pharmaceutical Executive
Vertex Pays $10 Billion to Enter Rare Endocrine Disease - TradingView
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks - Endpoints News
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal - Barron's
Recon: Vertex buys Crinetics for $10B; EMA fast tracks Revolution’s metastatic pancreatic cancer drug - RAPS
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion - Pharmaceutical Executive
RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $570 From $543, Maintains Outperform Rating - Moomoo
Crinetics Pharmaceuticals (CRNX) Agreed To A $10 Billion All Cash Sale To Vertex - simplywall.st
CRNX Soars On Vertex’s $10B Buyout And Tight Trading Range - StocksToTrade
FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka - Fierce Pharma
Endocrinology becomes Vertex’s fifth pillar with $10B Crinetics buy - BioWorld News
Compass says depression drug has long-lasting benefits - STAT
Vertex Pharmaceuticals (VRTX) Announces Strategic Merger with Cr - GuruFocus
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):